Qiming Venture Partners and Schrödinger to Co-host Small Molecule Drug Discovery Seminar

Dr. Lei Hui

Senior Vice President, Structure Therapeutics (NASDAQ: GPCR)(Chemistry)

Throughout her nearly 20-year career, Dr. Hui Lei has led multiple drug development projects covering a broad range of targets, including proteases, nuclear receptors, kinases, and GPCRs. These efforts have successfully yielded multiple clinical candidates for neuroinflammatory diseases, Alzheimer’s disease, and metabolic disorders. Prior to joining Sundia MediTech, she served as Vice President of Chemistry at Hejing Pharmaceuticals, where she established the drug discovery pipeline and fully strengthened and applied various technology platforms. Previously, Dr. Lei held the position of Deputy Director of R&D at Eli Lilly China and GlaxoSmithKline China, and she also held various roles at ChemPartner and CoMentis. Dr. Lei is an inventor on numerous international patents and holds a Ph.D. in Organic Chemistry from the University of Illinois at Chicago and a B.S. in Chemistry from Peking University.

Dr. Zou Yefen

Schrödinger Therapeutics Group

Yefen Zou is an experienced medicinal chemist who has been with Schrödinger for three years. Prior to joining Schrödinger, she spent 13 years at Novartis, focusing on the discovery of first-in-class novel drugs. As a project leader and medicinal chemist, she led multiple projects from hit identification to clinical candidate selection. At Schrödinger, Yefen Zou works closely with computational chemists to leverage the company’s technology platform for identifying virtual hits, performing de novo design of new molecules, and optimizing ADME properties and overall drug-like characteristics, thereby successfully delivering clinical candidates.

Dr. Yuqi Zhang

Schrödinger Platform R&D 

Yuqi Zhang is the Product Manager for Schrödinger’s docking technologies, responsible for enhancing and expanding the performance and applicability of Schrödinger’s docking tools, including Glide and WScore. Dr. Zhang earned his Ph.D. from Duke University, specializing in engineering charge transfer pathways in biological systems. He subsequently conducted postdoctoral research at The Scripps Research Institute, focusing on advancing peptide docking techniques.

Dr. Hu Xiaohu

Schrödinger Application Science

Hu Xiaohu is a senior computational biophysicist specializing in molecular dynamics modeling, with extensive experience in free energy calculations and the prediction of thermodynamic and kinetic properties of molecular systems using enhanced sampling techniques. He earned his Master’s degree in Physics from Heidelberg University in Germany and his Ph.D. from the University of Tennessee, Knoxville.

Prior to joining Schrödinger as an Applications Scientist in 2019, Dr. Xiaohu Hu served as a Postdoctoral Researcher at the Icahn School of Medicine at Mount Sinai in New York, where his research primarily focused on the pharmacology of G protein-coupled receptors (GPCRs). At Schrödinger, his primary responsibilities include providing consulting and advisory services to pharmaceutical and biotechnology companies, helping them leverage advanced computational methods to overcome challenges in drug design and discovery. Additionally, he leads various research projects aimed at developing novel computational methodologies, thereby further expanding the application scope of Schrödinger’s technologies.